<DOC>
	<DOC>NCT02786992</DOC>
	<brief_summary>This prospective randomized double-blind clinical trial will be conducted at Ain-Shams University Maternity Hospital, Cairo, Egypt. Patients eligible for elective lower segment cesarean section will be randomized to 2 groups. Group 1: will receive 400 ug misoprostol following + 10 IU oxytocin intravenous slowly after cord clamping. Group 2: will receive 100 ug carbetocin intravenous after cord clamping.</brief_summary>
	<brief_title>Misoprostol+Oxytocin vs. Carbetocin in CS</brief_title>
	<detailed_description />
	<mesh_term>Postpartum Hemorrhage</mesh_term>
	<mesh_term>Carbetocin</mesh_term>
	<mesh_term>Oxytocin</mesh_term>
	<mesh_term>Misoprostol</mesh_term>
	<criteria>Women with singleton pregnancy Women scheduled for elective CS full term (gestational age â‰¥37 weeks). hypersensitivity to oxytocin, carbetocin or prostaglandins contraindication to prostaglandins (e.g. glaucoma) history of significant heart disease severe asthma epilepsy history or evidence of liver renal or vascular disease history of coagulopathy thrombocytopenia or anticoagulant therapy women with HELLP syndrome eclampsia women presenting by placental abruption contraindication to spinal anesthesia as carbetocin is licensed for use with regional anesthesia only.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Misoprostol</keyword>
	<keyword>Oxytocin</keyword>
	<keyword>Carbetocin</keyword>
	<keyword>Prevention</keyword>
	<keyword>Post-partum hemorrhage</keyword>
</DOC>